Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Trevi Therapeutics (TRVI) is a clinical-stage biotech advancing Haduvio (oral nalbuphine ER) for chronic cough and pruritic conditions. Recent financing and conference activity have tightened the runway and investor attention; valuation is rich given development-stage fundamentals, but positive cough data and heavy short interest create a tacticall…
ServiceNow is positioned to report another AI-accelerated quarter. With a $29B backlog, $4.6B in free cash flow and improving technical momentum, the pieces point to a Q3 beat. This is a tactical swing long: enter at market, limit risk with a $115 stop, target $150 as investors re-rate durable AI workflow monetization.
Frontline plc (FRO) looks expensive to some screens - price near a 52-week high and elevated PB - but dividend yield (7.2%), improving tanker fundamentals and bullish momentum create a compelling mid-term trade. Entry $44.43, stop $39.00, target $52.00; mid-term (45 trading days) outlook.
Meta's shares have retraced sharply from last year's peak as a major child safety trial and broader market risk-off sentiment weigh on the name. At $550 today, the company still generates robust free cash flow ($40.98B) and trades at ~20x earnings, leaving room for upside if ad demand stabilizes and litigation proves containable. This note lays out…
PayPal’s board rejected a $60.50-per-share joint offer from Stripe and Advent International. With a $52B+ market cap, strong free cash flow and a low multiple profile, PayPal is an attractive takeover target that could prompt a renewed bid above the current $61 area. This note lays out an actionable trade: enter at $61.35, target $70.00, stop $58.0…
SK hynix sits at the intersection of secular AI memory demand and a highly consolidated supply base. For disciplined traders willing to tolerate memory cyclicality, a controlled long-term long can capture significant upside if industry economics and M&A dynamics accelerate.
Himax (HIMX) is a small-cap semiconductor specialist that quietly supplies display drivers, wafer-level optics and LCoS microdisplays into automotive and AR chains. The business combines in-house manufacturing, steady cash return via dividends, and recent product ramps (OLED touch controllers, Front-lit LCoS) that justify a tactical long. We lay ou…
Edesa Biotech, a clinical-stage biopharmaceutical company listed on Nasdaq, announced the pricing of an underwritten public offering expected to raise gross proceeds of approximately $25 million. The offering includes common shares and warrants, aimed at supporting general corporate purposes including working capital, capital expenditures, and adva…
Teradyne is benefiting from an AI-led memory and semiconductor cycle that is pushing test volume and complexity higher. Strong Q2 results and bullish guidance justify an upgraded buy, but near-term volatility and stretched multiples argue for a dip-entry approach. Trade plan included for a mid-term swing with clear entry, stop and target.
Elanco's recent quarterly beat, new emergency-use approvals, and continued pet-care tailwinds create a practical long trade with clearly defined entry, stop and target. The company trades at roughly $12.2B market cap, generates positive free cash flow, and carries moderate leverage - a setup where execution on product launches will control the next…
UiPath has moved from growth skepticism to hitting profitability, raising guidance and showing early success with agentic AI orchestration. With a market cap near $8.2B, attractive cash flow, improving margins and heavy short positioning, the risk/reward favors a tactical long over the next 45 trading days if ARR and execution continue to validate …
Oil prices were largely unchanged in early trade as investors weighed the risk of a wider U.S.-Iran conflict and ongoing uncertainty about shipping through the Strait of Hormuz. Brent rose slightly, U.S. WTI contracts moved unevenly, and U.S. stockpile data showed a larger-than-expected crude build alongside shifts in refined product inventories.
Telix Pharmaceuticals announced a 22% year-over-year revenue increase to $477 million in H1 2026, supported by strong sales growth in its precision medicine segment. The company achieved margin improvements and a 146% rise in adjusted EBITDA to $52 million, bolstered by a $40 million upfront payment from a strategic collaboration with Regeneron. Si…
The U.S. Education Department's office for civil rights has released guidance instructing schools that changing discipline policies with the specific aim of reducing racial disparities amounts to race discrimination. The guidance labels practices described as "racial balancing" as discriminatory and follows the department's removal last month of se…
Rigetti Computing announced a new organizational structure creating a dedicated Systems Delivery organization to enhance scaling of on-premises quantum system deployments and establishing a Chief Operating Officer role to oversee operations, manufacturing, systems delivery, and customer engagement. The shift allows the Chief Technology Officer to f…
Ascentage Pharma announced a 29% year-over-year revenue increase to $44.5 million for the first half of 2026, driven by product sales growth. The company expanded executive leadership to strengthen commercial capabilities and continues progressing nine registrational Phase III global clinical trials, including FDA and EMA-cleared studies of its onc…
Sensata Technologies is a sensor and electrical-protection specialist showing clear operational cash-generation and addressable-market tailwinds from EVs, charging infrastructure, and industrial electrification. The stock is trading below key moving averages with an attractive free-cash-flow yield versus peers; this trade targets a mid-term re-rati…
Journey Medical's Q2 narrative and commercial update show Emrosi gaining prescription traction despite reimbursement timing noise. At a $192M market cap, improving script flow, falling short interest and bullish technicals create a favorable risk/reward for a mid-term long trade. This idea includes a clear entry at $6.81, a $9.25 target and a $5.25…
Virtuix Holdings Inc. announced its first quarter fiscal year 2027 results, reporting a 72% year-over-year increase in new Omni One system orders and approximately 150% growth since the launch of Omni One for Quest in collaboration with Meta. Despite a decrease in net sales due to backlog completion, gross profit increased 29%, and gross margin exp…
Ocean Power Technologies announced updated preliminary financial results for fiscal year 2026 after additional audit procedures. The company revised its accounting treatment, resulting in a decrease in revenue from $4.1 million to $3.7 million and an increase in net loss from $43.7 million to $48.9 million. These changes do not reflect operational …
Picard Medical, Inc. (NYSE American: PMI), parent company of SynCardia Systems, reported a 39% increase in revenue to approximately $3.0 million for Q2 2026 and a 16% decrease in net loss compared to the prior year. The company made progress in its core business driven by US sales growth and improved gross profit margins. Additionally, Picard advan…
LightPath Technologies is increasingly relevant to Western defense and commercial optics supply chains. The company's infrared and thermal optics wins, low leverage, and recently strengthened balance sheet set up a tactical long. We lay out an actionable swing trade with clear entry, target and stop, plus the catalysts and risks that will move the …
Ultragenyx Pharmaceutical Inc. announced the FDA accelerated approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), the first-ever gene therapy approved to treat the underlying cause of Glycogen Storage Disease Type Ia (GSDIa). This approval provides a novel therapeutic option that reduces the burden of intensive cornstarch management for patient…
Encore Capital Group, a specialty finance company focused on debt recovery, has appointed Robert W. Beck to its Board of Directors. Beck brings over 30 years of experience in financial services, including leadership roles at Regional Management Corporation and Citigroup. He will serve on the Board's Audit and Risk Committees, enhancing governance a…
Odysight.ai Inc., an Israeli AI visual monitoring solutions provider, announced a confidentially marketed public offering of its common stock on Nasdaq and TASE. The company aims to raise capital to scale operations, enhance technology development, and expand in aerospace, Industry 4.0, transportation, and energy sectors. The offering is managed by…
